CompletedPhase 2NCT01222767
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
Studying Extraskeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PharmaMar
- Principal Investigator
- Fariba Navid, MDSt. Jude Children 's Research Hospital
- Intervention
- Zalypsis(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2010 – 2012
Study locations (7)
- Sarcoma Oncology Center, Santa Monica, California, United States
- St. Jude Children 's Research Hospital, Memphis, Tennessee, United States
- Seattle Cancer Care Alliance, Seattle, Washington, United States
- Centre Léon Bérard, Lyon, France
- Istituto Ortopedici Rizzoli, Bologna, Italy
- Istituto Nazionale dei Tumori, Milan, Italy
- Istituto Clinico Humanitas, Rozzano, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01222767 on ClinicalTrials.gov